bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 135 citations · 10 references
MedicineInfectious DiseasesPharmacologyClinical PharmacologyDrug DesignDrug DiscoveryAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyAnimal Model PharmacologyAntiviral Drug DesignAntiviral TherapeuticsAntiviral TreatmentFda Drug RegulationSars-cov-2 Antiviral TherapySars-cov-2 InfectionTherapeutic Antiviral Therapy
Abstract COVID-19 is an emerging infectious disease and was recently declared as a pandemic by WHO. Currently, there is no vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 μM < IC 50 < 10 μM) against SARS-CoV-2. In particular, two FDA-approved drugs - niclosamide and ciclesonide – were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.
10
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou, Xing‐Lou Yang, Xian-Guang Wang et al. · Nature · 2020 · 23.3K citations · Full text